

CLAIMS

9/B12
1. A method of lowering plasma glucagon in a subject, comprising administering to said subject a therapeutically effective glucagon lowering amount of a compound selected from the group consisting of an exendin, an an exendin agonist, a modified exendin and a modified exendin agonist.

2. The method of claim 1 wherein said subject is suffering from necrolytic migratory erythema.

10 3. The method of claim 1 wherein said subject has a glucagonoma.

9/024
4. The method of any of claims 1-3 wherein said exendin agonist is an exendin.

15 5. The method of claim 4 wherein said exendin is exendin-4.

6. The method of any of claims 1-3 or 4 wherein said subject is a human.

20 7. The method of any of claims 1-3 wherein said modified exendin or exendin agonist is linked to one or more polyethylene glycol polymers.

8. The method of claim 7, wherein said one or more polyethylene glycol polymers each have molecular weights between 500 and 20,000.